GlassScriptPhysician profile
Emily K Matthews
NPI 1639407331
$5,377.75
in general payments reported to CMS, 2019-2025
28 companies · $882 in 2025
The $882 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $437 · 2021: $679 · 2022: $1,360 · 2023: $770 · 2024: $657 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.18 |
| Education | $362.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,203.03 | 2019-2024 | |
| Janssen Biotech, INC. | $759.44 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $523.34 | 2019-2025 | |
| Lilly USA, LLC | $452.47 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $432.87 | 2021-2025 | |
| Hill Dermaceuticals, INC. | $319.54 | 2022-2024 | Tolak |
| Sun Pharmaceutical Industries INC. | $312.64 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $230.24 | 2024-2025 | Acthar |
| Pfizer INC. | $186.17 | 2019-2022 | |
| Organogenesis INC. | $161.04 | 2023-2025 | Cygnus Dual, Affinity, Novachor |
| Janssen Scientific Affairs, LLC | $114.46 | 2019 | |
| Leo Pharma INC. | $91.83 | 2019-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $86.58 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $69.44 | 2023-2025 | Dysport |
| Ucb, INC. | $62.50 | 2024-2025 | Bimzelx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.77 | 2020-2025 | Otezla |
| Merz North America, INC. | $42.78 | 2022 | |
| Incyte Corporation | $42.57 | 2021-2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $39.30 | 2021-2022 | |
| Convatec INC. | $31.93 | 2024 | |
| Biofrontera INC. | $31.40 | 2024 | Ameluz, Rhodoled Xl, Xepi |
| Organon LLC | $30.42 | 2025 | Vtama |
| Krystal Biotech INC | $24.80 | 2023 | Vyjuvek |
| Almirall LLC | $20.87 | 2021 | |
| Alon Medical Technology | $15.85 | 2024 | |
| Genentech USA, INC. | $15.36 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.75 | 2023 | Jublia |
| Mayne Pharma Commercial LLC | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.